Personal information

Activities

Employment (3)

Reinier de Graaf Hospital: Delft, Zuid-Holland, NL

2023-06-01 to present | Medical Immunologist in training (Medical Immunology)
Employment
Source: Self-asserted source
Jolien Van der Meer

Sanquin Research: Amsterdam, Noord-Holland, NL

2021-03-01 to 2023-05 | Post-doc (Hematopoiesis)
Employment
Source: Self-asserted source
Jolien Van der Meer

Radboud Universiteit Radboud Institute for Molecular Life Sciences: Nijmegen, Gelderland, NL

2016-11-01 to 2021-01-31 | PhD student (Laboratory Medicine, Laboratory of Hematology)
Employment
Source: Self-asserted source
Jolien Van der Meer

Works (7)

Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo

Cytotherapy
2024-04 | Journal article
Contributors: Said Z. Omar; Vera van Hoeven; Nienke J.E. Haverkate; Jolien M.R. Van der Meer; Carlijn Voermans; Bianca Blom; Mette D. Hazenberg
Source: check_circle
Crossref

Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer

Cytotherapy
2024-02 | Journal article
Contributors: Jolien M.R. Van der Meer; Ingrid Bulder; Carlijn Kuijk; Marion Kleijer; Myrddin W. Verheij; Said Z. Omar; Nienke J.E. Haverkate; Harry Dolstra; Bianca Blom; Mette D. Hazenberg et al.
Source: check_circle
Crossref

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells

Cancer Immunology, Immunotherapy
2021-11-15 | Journal article
Contributors: J. M. R. Van der Meer; R. J. A. Maas; K. Guldevall; K. Klarenaar; P. K. J. D. De Jonge; J. S. Hoogstad-van Evert; A. B. van der Waart; J. Cany; J. T. Safrit; J. H. Lee et al.
Source: check_circle
Crossref

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

Cancer Immunology, Immunotherapy
2021-05-03 | Journal article
Contributors: J. M. R. Van der Meer; R. J. A. Maas; K. Guldevall; K. Klarenaar; P. K. J. D. de Jonge; J. S. Hoogstad-van Evert; A. B. van der Waart; J. Cany; J. T. Safrit; J. H. Lee et al.
Source: check_circle
Crossref

CD34 + progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg null mice

OncoImmunology
2021-01 | Journal article
Contributors: Jolien M.R. Van der Meer; Paul K.J.D. de Jonge; Anniek B. van der Waart; Alexander C. Geerlings; Jurgen P. Moonen; Jolanda Brummelman; Janne de Klein; Malou C. Vermeulen; Ralph J.A. Maas; Nicolaas P.M. Schaap et al.
Source: check_circle
Crossref

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

OncoImmunology
2020-01 | Journal article
Contributors: Ralph Ja Maas; Janneke S Hoogstad-van Evert; Jolien Mr Van der Meer; Vera Mekers; Somayeh Rezaeifard; Alan J Korman; Paul Kjd de Jonge; Jeannette Cany; Rob Woestenenk; Nicolaas Pm Schaap et al.
Source: check_circle
Crossref

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.

Oncotarget
2018 | Journal article
WOSUID:

MEDLINE:30410679

Contributors: Hoogstad-van Evert, Janneke S; Maas, Ralph J; van der Meer, Jolien; Cany, Jeannette; van der Steen, Sophieke; Jansen, Joop H; Miller, Jeffrey S; Bekkers, Ruud; Hobo, Willemijn; Massuger, Leon et al.
Source: Self-asserted source
Jolien Van der Meer via ResearcherID